

Hansa Medical

Hansa Medical's Nomination Committee for the AGM 2019 Appointed and 2019 Financial Calendar Published

Lund, Sweden, October 25, 2018 - Hansa Medical AB (Nasdaq Stockholm: HMED), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced the appointment of the Nomination Committee for the Annual General Meeting (AGM) 2019 and the publication of the 2019 financial calendar.

In accordance with the decision of the AGM on May 29, 2018, a Nomination Committee for the Hansa Medical AGM 2019 has been formed. Based on the list of shareholders as of 31 August 2018, the three largest shareholders have been contacted and invited to each appoint a representative to the Nomination Committee. The Nomination Committee consists of Erika Kjellberg Eriksson representing Nexttobe AB, Astrid Samuelsson representing Handelsbanken Funds, Sven Sandberg representing Thomas Olausson and Gladiator. The Nomination Committee also includes the chairman of the board, Ulf Wiinberg, as convener.

The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of the chairman of the AGM, election of auditors (if applicable) and the auditors and proposals for rules for the Nominating Committee for the AGM in 2019.

The AGM of Hansa Medical AB (publ) will be held May 22, 2019 in the Auditorium (Hörsalen) by the Company's premises at Scheelevägen 22 in Lund.

Shareholders wishing to submit comments or proposals to the Nomination Committee may do so no later than March 27, 2019 via e-mail to info@hansamedical.com or by letter to Hansa Medical, Nomination Committee, Box 785, 220 07 Lund, Sweden. The Nomination Committee's proposals will be presented in the notice convening the AGM and on the Company's website.

Financial calendar

Year-end report 2018, 8 February 2019

Annual report 2018, 15 April 2019

Interim report for January – March 2019, 29 April 2019

Annual General Meeting 22 May, 2019

Interim report for January – June 2019, 18 July 2019

Interim report for January – September 2019, 31 October 2019

The information was submitted for publication, through the agency of the contact person set out below, at 8:00 am CEST on October 25, 2018.

About Hansa Medical

Hansa Medical (Nasdaq Stockholm: HMED) is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company's lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden.

For further information, please contact:

Hansa Medical

Company:

Emanuel Björne, Vice President Business Development and Investor Relations

Hansa Medical AB (Publ)

Mobile: +46707175477

E-mail: emanuel.bjorne@hansamedical.com

www.hansamedical.com

Swedish Investor and Media Relations:

Cord Communications

Mikael Widell

+46 70-311 99 60

U.K. Investor and Media Relations

FTI Consulting

Simon Conway/ Stephanie Cuthbert

+44 (0)20 3727 1000

U.S. Investor and Media Relations:

Argot Partners

Stephanie Marks / David Rosen (media)

+1 212 600 1902